Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer

• Status: Not yet recruiting
• Trial end date: 2022-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

Our study aims at assessment of response, survival and toxicity of frontline treatment with chemotherapy and Bevacizumab in patients having advanced epithelial ovarian cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nada Hassan Salah
• Collaborator: Assiut University
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Female patients diagnosed with advanced ovarian cancer by biopsy

• Age more than 18 years old

• Routine labs are within normal values ( CBC, renal function tests , liver function tests )

• Performance score 0-2

• FIGO stage II-IV

• Not having any contraindication to bevacizumab as : uncontrolled hypertension , bleeding tendency , ischaemic events

• Chemotherapy naïve.

• Informed consent

Exclusion Criteria:

• patients previously received chemotherapy or radiotherapy to any part of the abdomen or pelvis

• patients with uncontrolled infection

• patients with clinically significant cardiovascular disease

• patients with active bleeding or conditions associated with high risk of bleeding

• patients with history of CNS disease